论文部分内容阅读
目的:观察吉非替尼治疗老年晚期非小细胞肺癌临床疗效及不良反应。方法:40例患者,口服吉非替尼治疗,250 mg/d。结果:CR 2例,PR 10例,SD 11例,PD 17例,疾病控制率57.5%。不良反应为唑疮样皮疹46.7%(18/40),转氨酶升高7.14%(3/42)。结论:吉非替尼治疗老年晚期非小细胞肺癌疗效好,不良反应较微,能明显改善患者生活质量。
Objective: To observe the clinical efficacy and side effects of gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer. Methods: Forty patients were treated with gefitinib orally at 250 mg / d. Results: CR 2 cases, PR 10 cases, SD 11 cases, PD 17 cases, disease control rate 57.5%. Adverse reactions were azole-like rash 46.7% (18/40), transaminases increased 7.14% (3/42). Conclusion: Gefitinib treatment of elderly patients with advanced non-small cell lung cancer has good curative effect and mild side effects, which can significantly improve the quality of life of patients.